Jacob J Christensen1, Stine M Ulven2, Kjetil Retterstøl1, Ingunn Narverud3, Martin P Bogsrud4, Tore Henriksen5, Jens Bollerslev6, Bente Halvorsen7, Pål Aukrust8, Kirsten B Holven9. 1. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O box 1046 Blindern, 0317 Oslo, Oslo, Norway; The Lipid Clinic, Oslo University Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway. 2. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O box 1046 Blindern, 0317 Oslo, Oslo, Norway. 3. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O box 1046 Blindern, 0317 Oslo, Oslo, Norway; Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University, Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway. 4. The Lipid Clinic, Oslo University Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway; Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University, Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway. 5. Department of Obstetrics, Oslo University Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway; Faculty of Medicine, University of Oslo, P.O box 1046 Blindern, 0317 Oslo, Oslo, Norway. 6. Faculty of Medicine, University of Oslo, P.O box 1046 Blindern, 0317 Oslo, Oslo, Norway; Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway. 7. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, P.O box 1171 Blindern 0318 Oslo, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, P.O box 1171 Blindern 0318 Oslo, Oslo, Norway. 8. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, P.O box 1171 Blindern 0318 Oslo, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, P.O box 1171 Blindern 0318 Oslo, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway. 9. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O box 1046 Blindern, 0317 Oslo, Oslo, Norway; Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University, Hospital Rikshospitalet, P.O box 4950 Nydalen, 0424 Oslo, Oslo, Norway. Electronic address: k.b.holven@medisin.uio.no.
Abstract
BACKGROUND AND AIMS: Individuals with familial hypercholesterolemia (FH) have elevated low-density lipoprotein cholesterol (LDL-C), accelerated atherosclerosis, and premature cardiovascular disease. Whereas children with lifestyle-induced dyslipidemias often present with complex lipid abnormalities, children with FH have isolated hypercholesterolemia. However, to the best of our knowledge, a comprehensive profiling of FH children is lacking. Therefore, we aimed to characterize the lipid-related and metabolic alterations associated with elevated LDL-C in children with FH and healthy children. METHODS: We measured plasma metabolites in children with FH (n = 47) and in healthy children (n = 57) using a high-throughput nuclear magnetic resonance (NMR) spectroscopy platform, and compared the differences between FH and healthy children. RESULTS: Both statin treated (n = 17) and non-statin treated FH children (n = 30) had higher levels of atherogenic ApoB-containing lipoproteins and lipids, and lipid fractions in lipoprotein subclasses, compared to healthy children (n = 57). FH children displayed alterations in HDL particle concentration and lipid content, compared with healthy children. Interestingly, the small HDL particles were characterized by higher content of cholesteryl esters, and lower levels of free cholesterol and phospholipids. Furthermore, plasma fatty acids were higher in non-statin treated FH children, particularly linoleic acid. Finally, acetoacetate and acetate were lower in FH children compared with healthy children. CONCLUSIONS: Hypercholesterolemia in children associates with diverse metabolic repercussions and is more complex than previously believed. In particular, we found that hypercholesterolemia in FH children was paralleled not only by increased atherogenic ApoB-containing lipoproteins and lipid fractions, but also alterations in HDL subfractions that suggest impaired reverse cholesterol transport.
BACKGROUND AND AIMS: Individuals with familial hypercholesterolemia (FH) have elevated low-density lipoprotein cholesterol (LDL-C), accelerated atherosclerosis, and premature cardiovascular disease. Whereas children with lifestyle-induced dyslipidemias often present with complex lipid abnormalities, children with FH have isolated hypercholesterolemia. However, to the best of our knowledge, a comprehensive profiling of FHchildren is lacking. Therefore, we aimed to characterize the lipid-related and metabolic alterations associated with elevated LDL-C in children with FH and healthy children. METHODS: We measured plasma metabolites in children with FH (n = 47) and in healthy children (n = 57) using a high-throughput nuclear magnetic resonance (NMR) spectroscopy platform, and compared the differences between FH and healthy children. RESULTS: Both statin treated (n = 17) and non-statin treated FHchildren (n = 30) had higher levels of atherogenic ApoB-containing lipoproteins and lipids, and lipid fractions in lipoprotein subclasses, compared to healthy children (n = 57). FHchildren displayed alterations in HDL particle concentration and lipid content, compared with healthy children. Interestingly, the small HDL particles were characterized by higher content of cholesteryl esters, and lower levels of free cholesterol and phospholipids. Furthermore, plasma fatty acids were higher in non-statin treated FHchildren, particularly linoleic acid. Finally, acetoacetate and acetate were lower in FHchildren compared with healthy children. CONCLUSIONS:Hypercholesterolemia in children associates with diverse metabolic repercussions and is more complex than previously believed. In particular, we found that hypercholesterolemia in FHchildren was paralleled not only by increased atherogenic ApoB-containing lipoproteins and lipid fractions, but also alterations in HDL subfractions that suggest impaired reverse cholesterol transport.
Authors: Emil Jørsboe; Mette K Andersen; Line Skotte; Frederik F Stæger; Nils J Færgeman; Kristian Hanghøj; Cindy G Santander; Ninna K Senftleber; Lars J Diaz; Maria Overvad; Ryan K Waples; Frank Geller; Peter Bjerregaard; Mads Melbye; Christina V L Larsen; Bjarke Feenstra; Marit E Jørgensen; Niels Grarup; Ida Moltke; Anders Albrechtsen; Torben Hansen Journal: HGG Adv Date: 2022-06-09
Authors: Joel T Rämö; Pietari Ripatti; Rubina Tabassum; Sanni Söderlund; Niina Matikainen; Mathias J Gerl; Christian Klose; Michal A Surma; Nathan O Stitziel; Aki S Havulinna; Matti Pirinen; Veikko Salomaa; Nelson B Freimer; Matti Jauhiainen; Aarno Palotie; Marja-Riitta Taskinen; Kai Simons; Samuli Ripatti Journal: J Am Heart Assoc Date: 2019-06-29 Impact factor: 5.501
Authors: Sartaj Ahmad Mir; Li Chen; Peter J Meikle; Markus R Wenk; Neerja Karnani; Satvika Burugupalli; Bo Burla; Shanshan Ji; Adam Alexander T Smith; Kothandaraman Narasimhan; Adaikalavan Ramasamy; Karen Mei-Ling Tan; Kevin Huynh; Corey Giles; Ding Mei; Gerard Wong; Fabian Yap; Kok Hian Tan; Fiona Collier; Richard Saffery; Peter Vuillermin; Anne K Bendt; David Burgner; Anne-Louise Ponsonby; Yung Seng Lee; Yap Seng Chong; Peter D Gluckman; Johan G Eriksson Journal: BMC Med Date: 2022-07-25 Impact factor: 11.150
Authors: Stine M Ulven; Jacob J Christensen; Ottar Nygård; Asbjørn Svardal; Lena Leder; Inger Ottestad; Vegard Lysne; Johnny Laupsa-Borge; Per Magne Ueland; Øivind Midttun; Klaus Meyer; Adrian McCann; Lene F Andersen; Kirsten B Holven Journal: Am J Clin Nutr Date: 2019-05-01 Impact factor: 7.045
Authors: Jacob Amersfoort; Frank H Schaftenaar; Hidde Douna; Peter J van Santbrink; Gijs H M van Puijvelde; Bram Slütter; Amanda C Foks; Amy Harms; Estefania Moreno-Gordaliza; Yanyan Wang; Thomas Hankemeier; Ilze Bot; Hongbo Chi; Johan Kuiper Journal: Cardiovasc Res Date: 2021-04-23 Impact factor: 13.081